Intensity Therapeutics Stock Cools After-Hours Following 395% Surge: What You Should Know

All NewsOctober 31, 2025

Intensity Therapeutics shares plunged 31.9% after-hours following the publication of Phase 1/2 trial results for its cancer therapy INT230-6.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent